Biomarker
|
Group
|
N
1
| AUC |
---|
 |  |  |
CA/no CA
2
|
CA/benign
2
|
Abnormal/benign
2
|
---|
uPA+PAI-1 | All | 79 | .72 | .75 | .74 |
uPA3
| Pre | 38 | .87 | .83 | .86 |
TF4
| Post | 72 | .81 | .83 | .83 |
TF+uPA | All | 35 | .84 | .92 | .91 |
TF+uPA+PAI-1 | All | 24 | 1.0 | 1.0 | .97 |
-
1AUC: area under the receiver operating curve; uPA: urinary plasminogen activator; PAI (uPA inhibitor)-1, TF: Thomsen-Friedenreich antigen; N = number or sample size. The equivalent values as percent should be multiplied by 100 (i.e., .97 = 97%, and so forth)
-
2Cancer = ductal carcinoma in situ (DCIS), and invasive cancer; Benign = normal and hyperplasia; Abnormal = atypical hyperplasia, DCIS, and invasive cancer. Age is in all three models
-
3AUC values for postmenopausal women were lower
-
4previously published data [9]